Finance

Lists
B1SX34:BVMF
Boston Scientific Corp Brazilian Depositary Receipt
53,34 R$
0,00%
(0,00) 1D
9 ოქტ, 16:56:00 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for B1SX34...
Open
52,72 R$
High
53,34 R$
Low
52,50 R$
Mkt. cap
62,22 მლრდ.
Avg. vol.
1,02 ათ.
Volume
67,00
52-wk high
140,91 R$
52-wk low
50,29 R$
Shares outstanding
1,45 მლრდ.
No. of employees
59 ათ.
Open
52,72 R$
High
53,34 R$
Low
52,50 R$
Mkt. cap
62,22 მლრდ.
Avg. vol.
1,02 ათ.
Volume
67,00
52-wk high
140,91 R$
52-wk low
50,29 R$
Shares outstanding
1,45 მლრდ.
No. of employees
59 ათ.
News stories
From web sources and news partners
Profile
Boston Scientific Corporation is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. The company is known for developing the Taxus Stent, a drug-eluting stent that is used to open clogged arteries. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware. Wikipedia
About Boston Scientific Corp Brazilian Depositary Receipt
CEOმაიკლ ეფ მაჰონი
Employees59 ათ.
Founded29 ივნ. 1979
HeadquartersMarlborough, მასაჩუსეტსი, ამერიკის შეერთებული შტატები
SectorMedical device
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
5,06 მლრდ.
5,29 მლრდ.
5,20 მლრდ.
5,44 მლრდ.
Cost of goods sold
1,54 მლრდ.
1,61 მლრდ.
1,60 მლრდ.
1,61 მლრდ.
Cost of revenue
1,54 მლრდ.
1,61 მლრდ.
1,60 მლრდ.
1,61 მლრდ.
Research and development expenses
514,00 მლნ.
569,00 მლნ.
516,00 მლნ.
554,00 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,74 მლრდ.
1,83 მლრდ.
1,78 მლრდ.
1,80 მლრდ.
Operating expense
2,48 მლრდ.
2,63 მლრდ.
2,53 მლრდ.
2,59 მლრდ.
Total operating expenses
4,02 მლრდ.
4,24 მლრდ.
4,13 მლრდ.
4,20 მლრდ.
Operating income
1,05 მლრდ.
1,04 მლრდ.
1,07 მლრდ.
1,25 მლრდ.
Other non operating income
-16,00 მლნ.
28,00 მლნ.
28,00 მლნ.
-6,00 მლნ.
EBT including unusual items
938,00 მლნ.
700,00 მლნ.
1,16 მლრდ.
1,06 მლრდ.
EBT excluding unusual items
935,00 მლნ.
1,01 მლრდ.
999,00 მლნ.
1,14 მლრდ.
Income tax expense
183,00 მლნ.
30,00 მლნ.
-176,00 მლნ.
155,00 მლნ.
Effective tax rate
19,51%
4,29%
-15,13%
14,62%
Other operating expenses
-
-
-
-
Net income
755,00 მლნ.
672,00 მლნ.
1,34 მლრდ.
907,00 მლნ.
Net profit margin
14,91%
12,71%
25,77%
16,67%
Earnings per share
0,75
0,80
0,80
0,86
Interest and investment income
-
29,00 მლნ.
-
11,00 მლნ.
Interest expense
-87,00 მლნ.
-90,00 მლნ.
-90,00 მლნ.
-96,00 მლნ.
Net interest expenses
-87,00 მლნ.
-61,00 მლნ.
-90,00 მლნ.
-85,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
1,39 მლრდ.
1,41 მლრდ.
1,42 მლრდ.
1,60 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები